Cephalon Extends Deadline On Arana Buyout In Hopes Of Making The Aussie Biotech A Wholly Owned Subsidiary
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Cephalon International Holdings has extended its deadline to June 15 for its acquisition of Australian biotech Arana shares in hopes of gaining 90 percent control of the target company, and then transforming it into a wholly owned subsidiary
You may also be interested in...
What Financial Crisis? Australian Biotech Enters Golden Era (Part 2 of 2)
PERTH, Australia - As Australia's biotech sector comes of age, it is beginning to attract the attention of multinational companies, as evidenced by stepped-up merger and acquisition activity and rounds of new funding in the last six months
What Financial Crisis? Australian Biotech Enters Golden Era (Part 2 of 2)
PERTH, Australia - As Australia's biotech sector comes of age, it is beginning to attract the attention of multinational companies, as evidenced by stepped-up merger and acquisition activity and rounds of new funding in the last six months
Cephalon Lands Option To Buy BioAssets For $30 Mil., Eying Anti-TNFs In Sciatica
Cephalon hopes BioAssets' sciatic pain proof-of-concept study for etanercept will pave a development path for its anti-TNF.